BioSpectrum-ABLE Biotech Industry Survey, 2013

4

description

Biocon Ranked at No 2 and Syngene at No 5“Having forged strategic partnerships with the Mylan and BMS to consolidate its key insulin business, Biocon emerged even stronger in 2012” - Kiran Mazumdar-Shaw, Chairman and Managing Director

Transcript of BioSpectrum-ABLE Biotech Industry Survey, 2013

Page 1: BioSpectrum-ABLE Biotech Industry Survey, 2013
Page 2: BioSpectrum-ABLE Biotech Industry Survey, 2013
Page 3: BioSpectrum-ABLE Biotech Industry Survey, 2013
Page 4: BioSpectrum-ABLE Biotech Industry Survey, 2013